We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Associations of disease duration and anti-citrullinated peptide antibody status with the effectiveness of abatacept in biologic-naïve patients with rheumatoid arthritis: Post hoc analysis of a multicentre, real-world observational study in Japan (ORIGAMI)
- Authors
Kenta Misaki; Naoto Tamura; Takanori Azuma; Koichiro Shinoda; Masao Tanaka; Hiroshi Fujiwara; Hideki Tsuboi; Tsuyoshi Kasama; Ryusuke Yoshimi; Tadamasa Hanyu; Yoshiaki Kusaka; Makoto Hirao; Makoto Onishi; Ayumi Uchino; Tomomasa Izumiyama; Kwang-Seok Yang; Noriyoshi Ogawa; Kiyoshi Matsui; Kazuhiro Kurasawa; Satoshi Kawaai
- Abstract
Objectives: The aim of the article is to investigate the associations of disease duration and anti-cyclic citrullinated peptide antibody (ACPA) status with the effectiveness of abatacept in biologic-naïve patients with rheumatoid arthritis (RA). Methods: We performed post hoc analyses of the Orencia® Registry in Geographically Assembled Multicenter Investigation (ORIGAMI) study of biologic-naïve RA patients aged ≥20 years with moderate disease activity who were prescribed abatacept. Changes in the Simplified Disease Activity Index (SDAI) and Japanese Health Assessment Questionnaire (J-HAQ) at 4, 24, and 52 weeks of treatment were analysed in patients divided according to ACPA serostatus (positive/negative), disease duration (<1/≥1 year), or both. Results: SDAI scores decreased from baseline in all groups. SDAI scores tended to decrease more in the ACPA-positive group and disease duration <1-year group than in the ACPA-negative group and disease duration ≥1-year group, respectively. In the disease duration <1-year group, SDAI tended to decrease more in the ACPA-positive group than in the ACPA-negative group. Disease duration was independently associated with the change in SDAI and SDAI remission at Week 52 in multivariable regression models. Conclusions: These results suggest that starting abatacept within 1 year of diagnosis was associated with greater effectiveness of abatacept in biologic-naïve patients with RA and moderate disease activity.
- Subjects
DISEASE duration; PEPTIDES; RHEUMATOID arthritis; ABATACEPT; IMMUNOGLOBULINS; REGRESSION analysis
- Publication
Modern Rheumatology, 2024, Vol 34, Issue 2, p297
- ISSN
1439-7595
- Publication type
Article
- DOI
10.1093/mr/road045